RANBP10

Across TCGA pan-cancer cohorts, RANBP10 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RANBP10 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RANBP10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RANBP10 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where RANBP10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.220	0.542	.004	23	view →
LSCC	OS	Tertile	All	0.838	1.000	<.001	19	view →
HNSC	OS	Median	II,III,IV	1.000	0.925	.002	16	view →
LUAD	OS	Median	II,III,IV	0.609	0.881	.021	4	view →
CCRCC	DFS	Tertile	II,III,IV	0.915	0.399	.040	3	view →
GBM	DFS	Median	All	0.296	0.445	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RANBP10–PDAC (DFS)

Open the PDAC breakdown →